Phio Pharmaceuticals Corp. · NASDAQ:PHIO
Phio Pharmaceuticals — RXi Pharmaceuticals — 15th Annual Biotech in Europe Forum for Global Partnering and Investment Conference 2015
7 slides from Phio Pharmaceuticals's conference presentation, Sep 29, 2015
Slide 1: RXi Pharmaceuticals: Platform Technologies and Novel Therapeutics
Exhibit 99.2 RXi Pharmaceuticals NASDAQ: RXII Panel: Platform Technologies and ® Novel Therapeutics 15th Annual Biotech in Europe Forum for Global Partnering and Investment Conference September 29, 2015
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believes,” “anticipates,” “plans,” “expects,” “indicates,” “will,” “intends,” “potential,” “suggests” and similar expressions ar
Slide 3: From Platform to Product Company
From Platform to Product Company How Patients have Suffered in the Transition Platforms build on creative new ideas that can be broadly applied in drug development Platform companies struggle because their value is determined by ultimate product success Result: Companies disappear or the value of th
Slide 4: Platform Technologies & Novel Therapeutics
Platform Technologies & Novel Therapeutics Challenge: Evolve from a Platform-based Company into a Product- based Company while preserving the total value and potential of the Company. Solution: Identify innovative ways to capitalize on portions of the platform outside the Company’s strategic core fo
Slide 5: Transition Platform to Product Company
Transition Platform to Product Company Maintain Optimum Use of Innovation Strategic identification of the disease areas in which your Identify company wants to compete and which allow for demonstration of proof of concept of the platform in the near term 1–3 product candidates from your platform for
Slide 6: Example: RXi Pharmaceuticals
Example: RXi Pharmaceuticals Transition from Platform to Product Company Started as platform RNAi company Transformational self-delivering RNAi (sd-rxRNA ®) platform Multiple potential disease area targets Core Focus: Dermatology & Ophthalmology selected for product development Collaborations ongoin
Slide 7: sd-rxRNA: RXi's Proprietary Platform
® sd-rxRNA : RXi’s Proprietary Platform RXi’s unique sd-rxRNA platform allows for rapid identification of lead compounds for multiple targets in different therapeutic areas RXi’s Strategic Core Focus Dermatology Ophthalmology Scarring (fibrosis) Retinal scarring Hyperpigmentation disorders AMD, PVR